4.6 Review

PharmVar GeneFocus: CYP3A5

期刊

CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 112, 期 6, 页码 1159-1171

出版社

WILEY
DOI: 10.1002/cpt.2563

关键词

-

资金

  1. Children's Mercy Research Institute
  2. National Institutes of Health [U24 HG010615, R35GM140845]
  3. Swedish Research Council [2016-01153, 2016-01154, 2019-01837]
  4. EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN) [875510]
  5. Robert Bosch Foundation, Stuttgart, Germany
  6. Canadian Institute of Health Research Tier 2 Canada Research Chair in Pharmacogenomics and Precision Medicine
  7. Russian Federation
  8. National Human Genome Research Institute [U01 HG010245]

向作者/读者索取更多资源

This article introduces the star (*) allele nomenclature for the polymorphic human CYP3A5 gene in PharmVar, and summarizes the standardized nomenclature of this gene. Additionally, it discusses recent changes and updates, including the retirement of several allelic variants, and provides an overview of how the PharmVar CYP3A5 star allele nomenclature is utilized by PharmGKB and CPIC.
The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature for the polymorphic human CYP3A5 gene. Genetic variation within the CYP3A5 gene locus impacts the metabolism of several clinically important drugs, including the immunosuppressants tacrolimus, sirolimus, cyclosporine, and the benzodiazepine midazolam. Variable CYP3A5 activity is of clinical importance regarding tacrolimus metabolism. This GeneFocus provides a CYP3A5 gene summary with a focus on aspects regarding standardized nomenclature. In addition, this review also summarizes recent changes and updates, including the retirement of several allelic variants and provides an overview of how PharmVar CYP3A5 star allele nomenclature is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据